MyAI Registry for People with Adrenal Insufficiency
Trial Objectives
To help better understand adrenal insufficiency (AI) and its progression, researchers have developed a new registry called MyAI. Information collected via online surveys for the registry will help researchers learn about patient experiences with the illness and how it is impacting their lives. Researchers also will use the data to assess the effectiveness of current treatments and identify common causes and risk factors for AI. Adults, as well as children from birth to age 18, who have been diagnosed with AI or who are at high risk of developing the disease are needed to participate in the registry.
Who Can Participate
Group 1: People with known adrenal insufficiency
Group 2: At-risk of adrenal insufficiency due to drug treatments, family history or autoimmune disease
Group 3: Control group. People with no adrenal disease or family history of adrenal disease, and people who have not been treated with high-risk drugs such as prednisone, dexamethasone or opiates
Age: All Ages Gender: Any
Estimated Time Commitment
Initial online survey will take 30 minutes. Follow-up surveys every six months will take five to 10 minutes. Total time involvement is 10-20 years.
Payment & Reimbursement
Payment: Not Provided
Travel Reimbursement: Not Available
Trial Location
National Jewish Main Campus, Denver, CO
Trial Sponsors
National Adrenal Diseases Foundation
Principal Investigators
Elizabeth Anne Regan, MD, PhD